T2 Biosystms Stock Beneish M Score

TTOO Stock  USD 0.57  0.07  14.00%   
This module uses fundamental data of T2 Biosystms to approximate the value of its Beneish M Score. T2 Biosystms M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out T2 Biosystms Piotroski F Score and T2 Biosystms Altman Z Score analysis.
To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.
  
At this time, T2 Biosystms' Net Debt is very stable compared to the past year. As of the 1st of December 2024, Short Term Debt is likely to grow to about 46.7 M, while Short and Long Term Debt Total is likely to drop about 42 M. At this time, T2 Biosystms' Days Sales Outstanding is very stable compared to the past year. As of the 1st of December 2024, Days Of Inventory On Hand is likely to grow to 120.22, while Price To Sales Ratio is likely to drop 2.16.
At this time, it appears that T2 Biosystms is an unlikely manipulator. The earnings manipulation may begin if T2 Biosystms' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by T2 Biosystms executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of T2 Biosystms' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-2.5
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables

1.13

Focus
Asset Quality

0.13

Focus
Expense Coverage

0.73

Focus
Gross Margin Strengs

1.05

Focus
Accruals Factor

0.73

Focus
Depreciation Resistance

0.49

Focus
Net Sales Growth

1.36

Focus
Financial Leverage Condition

0.84

Focus

T2 Biosystms Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if T2 Biosystms' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables2.2 M1.4 M
Way Up
Slightly volatile
Total Revenue9.8 M7.2 M
Significantly Up
Slightly volatile
Total Assets43.7 M34.8 M
Significantly Up
Pretty Stable
Total Current Assets35.3 M25.2 M
Significantly Up
Pretty Stable
Non Current Assets Total11.6 M9.6 M
Fairly Up
Slightly volatile
Property Plant Equipment9.5 M15.3 M
Way Down
Slightly volatile
Depreciation And Amortization1.1 M859 K
Significantly Up
Slightly volatile
Selling General Administrative26 M26.1 M
Slightly Down
Slightly volatile
Total Current Liabilities59 M56.2 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total6.3 M6.7 M
Notably Down
Slightly volatile
Short Term Debt46.7 M44.5 M
Sufficiently Up
Slightly volatile
Long Term Debt29.1 M57.1 M
Way Down
Slightly volatile

T2 Biosystms Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between T2 Biosystms' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards T2 Biosystms in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find T2 Biosystms' degree of accounting gimmicks and manipulations.

About T2 Biosystms Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

1.15 Million

At this time, T2 Biosystms' Depreciation And Amortization is very stable compared to the past year.

T2 Biosystms Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as T2 Biosystms. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201920202021202220232024 (projected)
Net Receivables2.8M5.1M5.1M2.2M1.4M2.2M
Total Revenue8.3M18.1M28.1M22.3M7.2M9.8M
Total Assets28.5M79.1M60.5M34.4M34.8M43.7M
Total Current Assets18.9M53.6M44.4M19.4M25.2M35.3M
Net Debt33.7M39.0M34.9M48.9M33.8M35.5M
Short Term Debt42.9M1.2M1.2M2.7M44.5M46.7M
Operating Income(52.1M)(41.4M)(43.0M)(55.5M)(49.7M)(52.1M)
Investments(761K)(35.5M)25.3M9.7M(202K)(212.1K)
Gross Profit Margin(1.01)(0.17)0.260.0523(1.14)(1.19)

About T2 Biosystms Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze T2 Biosystms's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of T2 Biosystms using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of T2 Biosystms based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether T2 Biosystms offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of T2 Biosystms' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of T2 Biosystms Stock. Outlined below are crucial reports that will aid in making a well-informed decision on T2 Biosystms Stock:
Check out T2 Biosystms Piotroski F Score and T2 Biosystms Altman Z Score analysis.
To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.03)
Revenue Per Share
0.999
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.90)
Return On Equity
(6.22)
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.